EZETIMIBE: POSSIBILITIES AND PROSPECTS OF LIPID-MODIFYING THERAPY IN DIABETES MELLITUS
DOI:
https://doi.org/10.30890/2709-2313.2023-16-03-020Keywords:
0Abstract
Diabetes mellitus (DM) is a well-recognized risk factor for cardiovascular diseases, so an “aggressive” therapeutic approach is necessary for some high-risk patients. Low-density lipoprotein cholesterol (LDL-C) is the leading modifiable risk factor for thMetrics
References
Sabatine M.S., Giugliano R.P., Keech A.C. et al.; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722.
Joseph J.J., Deedwania P., Acharya T. et al.; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation. 2022 Mar;145(9):e722-e759.
Veilleux A., Grenier E., Marceau P. et al. Intestinal lipid handling: evidence and implication of insulin signaling abnormalities in human obese subjects. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):644-653.
Sahebkar A., Simental-Mendía L.E., Pedone C. et al. Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. Br J Clin Pharmacol. 2016 May;81(5):807-818.
Cai R., Yuan Y., Sun J. et al. Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis. Expert Opin Pharmacother. 2016 Oct;17(14):1839-1849.
Cui J.Y., Zhou R.R., Han S. et al. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis. J Clin Pharm Ther. 2018 Aug;43(4):556-570.
Mach F., Baigent C., Catapano A.L. et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188.
Serhiyenko V.A., Serhiyenko A.A. Diabetes and Cardiovascular Diseases. - Lviv: Kvart - 2022. - 352 с. ISBN 978-617-7196-32-6.
Dormuth C.R., Filion K.B., Paterson J.M. et al.; Canadian Network for Observational Drug Effect Studies Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ. 2014 May 29;348:g3244.
Sakamoto K., Kawamura M., Kohro T, et al.; RESEARCH Study Group. Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins. PLoS One. 2015 Sep 23;10(9):e0138332.
Tsunoda F., Asztalos I.B., Horvath K.V. et al. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial. Atherosclerosis. 2016 Apr;247:35-39.
Bardolia C., Amin N.S., Turgeon J. Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol. Front Cardiovasc Med. 2021 Nov 17;8:789931.
De Luca L., Corsini A., Uguccioni M. et al. Statins plus ezetimibe in the era of proprotein convertase subtilisin/ kexin type 9 inhibitors. Kardiol Pol. 2020 Sep 25;78(9):850-860.
Le N.A., Tomassini J.E., Tershakovec A.M. et al. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease. J Am Heart Assoc. 2015 Oct 20;4(10):e001675.
Chang S.H., Wu L.S., Lee C.H. et al. Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study. Int J Cardiol. 2015;190:20-25.
Liu C.H., Chen T.H., Lin M.S. et al. Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients. J Clin Endocrinol Metab. 2016 Aug;101(8):2994-3001.
Ahmed O., Littmann K., Gustafsson U. et al. Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients. J Am Heart Assoc. 2018 Dec 18;7(24):e009876.
Huang Z., Li Q., Ye W. et al. Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study. Chem Pharm Bull (Tokyo). 2019;67(5):419-425.
Hwang Y.C., Jun J.E., Jeong I.K. et al. Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2019 Oct;43(5):582-589.
Miao X.Y., Liu H.Z., Jin M.M. et al. A comparative meta-analysis of the efficacy of statin-ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2302-2310.
Hammersley D., Signy M. Ezetimibe: an update on its clinical usefulness in specific patient groups. Ther Adv Chronic Dis. 2017 Jan;8(1):4-11.
Ciriacks K., Coly G., Krishnaswami S. et al. Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus. Metab Syndr Relat Disord. 2015. 13(2). 84-90.
Pradhan A., Bhandari M., Sethi R. Ezetimibe, and Improving Cardiovascular Outcomes: Current Evidence and Perspectives. Cardiol Res Pract. 2020 Jun 28;2020:9815016.
Huang C.S., Yu X., Fordstrom P. et al. Cryo-EM structures of NPC1L1 reveal mechanisms of cholesterol transport and ezetimibe inhibition. Sci Adv. 2020 Jun 19;6(25):eabb1989.
Cosentino F., Grant P.J., Aboyans V. et al.; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323.
Jellinger P.S. American Association of Clinical Endocrinologists/American College of Endocrinology Management of Dyslipidemia and Prevention of Cardiovascular Disease Clinical Practice Guidelines. Diabetes Spectr. 2018 Aug;31(3):234-245.
Giugliano R.P., Cannon C.P., Blazing M.A. et al.; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 Apr 10;137(15):1571-1582.
Nakamura A., Sato K., Kanazawa M. et al. Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease. Heart Vessels. 2019 Jun;34(6):916-925.
Cannon C.P., Blazing M.A., Giugliano R.P. et al.; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-2397.
Rudofsky G., Reismann P., Groener J.B. et al. Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe. Atherosclerosis. 2012 Jul;223(1):190-196.
Wang J., Ai X.B., Wang F. et al. Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. Int Angiol. 2017 Oct;36(5):467-473.
Yang Y.J., Lee S.H., Kim B.S. et al. Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk. Clin Ther. 2017 Jan;39(1):107-117.
Swindle J.P., Ye X., Mallick R. et al. Colesevelam, Ezetimibe, and Patients With Type 2 Diabetes Mellitus: Characteristics and Clinical Outcomes From a Health Care Database. Ann Pharmacother. 2014 Jul;48(7):847-855.
Krysiak R., Zmuda W., Okopien B. The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia. Cardiovasc Ther. 2014 Apr;32(2):40-46.
Rizos C.V., Kostapanos M.S., Rizos E.C. et al. The effect of rosuvastatin on low-density lipoprotein subfractions in patients with impaired fasting glucose. J Cardiovasc Pharmacol Ther. 2015 May;20(3):276-283.
Kim K.J., Kim S.H., Yoon Y.W. et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc Ther. 2016 Oct;34(5):371-382.
Tsunoda T., Nozue T., Yamada M. et al. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract. 2013 Apr;100(1):46-52.
Saito I., Azuma K., Kakikawa T. et al. A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia. Lipids Health Dis. 2015 May 1;14:40.
Zafrir B., Jain M. Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms, and clinical implications. Cardiovasc Drugs Ther. 2014 Aug;28(4):361-77.
Wu H., Shang H., Wu J. Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2018 May;60(2):229-239.
Chang E., Kim L., Choi J.M. et al. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition. Metabolism. 2015 May;64(5):633-641.
Lee Y.B., Kim B., Han K. et al. Combination of Statin and Ezetimibe versus Statin Monotherapy on Cardiovascular Disease and Type 2 Diabetes Incidence among Adults with Impaired Fasting Glucose: a Propensity-Matched Nationwide Cohort Study. J Lipid Atheroscler. 2021 Sep;10(3):303-312.
Barkas F., Elisaf M., Liberopoulos E. et al. Statin therapy with or without ezetimibe and the progression to diabetes. J Clin Lipidol. 2016 Mar-Apr;10(2):306-313.
Takeshita M., Tanaka A., Kawagushi A. et al; On behalf of the EUCLID Study Investigators. The effect of switching from statin-monotherapy to statin/ezetimibe combination therapy on lipid profiles in patients with type 2 diabetes and dyslipidemia: a multicenter open-label study (EUCLID). Vasc Fail 2020 Jan;4(1):22-31.
Shin K.H., Choi H.D. Comparison of Efficacy and Safety of Statin-Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies. Am J Cardiovasc Drugs. 2022 Jul;22(4):395-406.
Torimoto K., Okada Y., Mori H. et al. Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 2013 Sep 22;12:137.
Sugiyama S., Jinnouchi H., Hieshima K. et al. A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus. Lipids Health Dis. 2015 Apr 23;14:37.
Inazawa T., Sakamoto K., Kohro T. et al.; RESEARCH Study Group. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale. Lipids Health Dis. 2013 Oct 5;12:142.
Sakamoto K., Kawamura M., Watanabe T. et al.; RESEARCH Study Group. Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. Lipids Health Dis. 2017 Jun 24;16(1):122.
Tsujita K., Sugiyama S., Sumida H. et al.; PRECISE–IVUS Investigators. Impact of Dual Lipid-Lowering Strategy with Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol. 2015 Aug 4;66(5):495-507.
Razzack A., Ahmed F., Thompson A. et al. Synergistic effect of ezetimibe and statin on lipoproteins in patients with type 2 diabetes mellitus-a systematic review and meta-analysis. J Am Coll Cardiol. 2021 May, 77(18 Suppl. 1):1618.
Hong N., Lee Y.H., Tsujita K. et al. Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis. Endocrinol Metab (Seoul). 2018 Jun;33(2):219-227.
Yu M., Liang C., Kong Q. et al. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. Lipids Health Dis. 2020 Jan 4;19(1):1.
Zhu Y., Hu H., Yang J. et al. The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: A meta-analysis. Bosn J Basic Med Sci. 2020 May 1;20(2):169-182.
Visseren F.LJ., Mach F., Smulders Y.M. et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3237.
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082-e1143.
Luo L., Yuan X., Huang W. et al. Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis. Intern Med J. 2015 May;45(5):546-557.
Nishikido T., Oyama J., Keida T. et al. High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial. J Cardiol. 2016 Apr;67(4):340-346.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
